Akcea Therapeutics, Inc. (AKCA)
(Delayed Data from NSDQ)
$26.01 USD
+0.60 (2.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.01 USD
+0.60 (2.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.
Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
BioNTech (BNTX) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session
by Zacks Equity Research
Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Retrophin (RTRX) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Neoleukin Therapeutics (NLTX) Looks Good: Stock Adds 9.4% in Session
by Zacks Equity Research
Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
by Zacks Equity Research
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Incyte (INCY) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
Incyte (INCY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
All You Need to Know About Akcea Therapeutics (AKCA) Rating Upgrade to Strong Buy
by Zacks Equity Research
Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.